Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Bonhams 1793 Limited in connection with its acquisition of Bukowski
Mandate

Vinge advises Bonhams 1793 Limited in connection with its acquisition of Bukowski

January 11, 2022 M&A

Vinge has advised Bonhams 1793 Limited, an international auction house with its head office in London, and a portfolio company of Epiris LLP, in connection with its acquisition of Bukowski Auktioner Aktiebolag (”Bukowski”).

Bukowski is an auction house within art and antiquities with its head office in Berzelii Park in Stockholm. The company also has a Finnish Subsidiary, Bukowski Oy. Through the acquisition, Bonhams will extend its geographical presence in Europe.

Vinge’s team consisted of, among others, Christina Kokko, Isabelle Wållgren, Hannah Kajlinger, Christa Anttila, Vilhelm Rondahl and Ellen Åkerdahl Flygt (M&A), Anton Sjökvist and Caroline Krassén (Financial Services), Tove Lövgren Frisk (Compliance), Karl-Hugo Engdahl (GDPR, IT), Ulf Pyk (Real Estate), Karolina Fuhrman and Isabell Nielsen (Corporate Commercial), Arvid Axelryd (IP), Emil Lindvall and Gustav Lindgren (Employment) as well as Sara Dahlros Sköld (VDR).

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026